Instrument Inactif

Autres langues Lannett Company, Inc. Nyse MKT

Actions

LCI

US5160121019

Produits pharmaceutiques

Autres langues

30/05	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination
19/05	FDA Approves Lannett, Lanexa Biologics, And Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar
04/05	Lanexa Biologics LLC Announces FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus
30/07/25	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.
16/06/23	Lannett Company, Inc. Emerges as a Private Company with New Board of Directors
16/06/23	Lannett Company, Inc. Emerged from Bankruptcy
08/06/23	First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.
05/06/23	First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.
15/05/23	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
04/05/23	Motion for Joint Administration Approved for Lannett Company, Inc.
04/05/23	Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.
03/05/23	Global markets live: Ford, AMD, Starbucks, Estee Lauder, CVS Health....
03/05/23	Bolsa de Madrid: SuperPowell Wanted
03/05/23	Motion for Joint Administration Filed by Lannett Company, Inc.
03/05/23	LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION
02/05/23	Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.
02/05/23	Lannett Company, Inc. Filed for Bankruptcy
01/05/23	Lannett Company, Inc. Enters Into Restructuring Support Agreement
25/04/23	Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index
20/04/23	NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
14/04/23	LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
14/04/23	John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023
14/04/23	John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023
04/04/23	LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)
04/04/23	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial